The Retinoic Acid Pathway Therapeutics Market
完整報告名稱與涵蓋範圍
The Retinoic Acid Pathway Therapeutics Market Size, Share & Trends Analysis Distribution by Product Type (Retinoic Acid Receptor Agonists (RAR Agonists), Retinoid X Receptor Agonists (RXR Agonists), RAR and RXR Dual Agonists, Others (Novel/Next-Generation Retinoic Acid Derivatives)), Application, Route of Administration, Distribution Channel, End-user and Segment Forecasts, 2024-2031
報告摘要
Across the 2024 to 2031 projection horizon, the worldwide The Retinoic Acid Pathway Therapeutics Market is projected to register a CAGR of 7.4%.
The Retinoic Acid Pathway Therapeutics covers The retinoic acid pathway therapeutics market represents a fast-emerging field dealing with the discovery and application of retinoic acid, which represents a vitamin A metabolite, in a variety of medical therapies. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Growth is underpinned by a convergence of factors: rising awareness among end users, continuous product innovation, and the growing emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region projected to deliver the strongest growth trajectory through the forecast period, underpinned by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Retinoic Acid Pathway Therapeutics Market Snapshot
Chapter 4. Global Retinoic Acid Pathway Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Retinoic Acid Pathway Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on RETINOIC ACID PATHWAY THERAPEUTICS MARKET Industry Trends
Chapter 5. Retinoic Acid Pathway Therapeutics Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share by Product Type, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Product Type:
5.2.1. Retinoic Acid Receptor Agonists (RAR Agonists)
5.2.2. Retinoid X Receptor Agonists (RXR Agonists)
5.2.3. RAR and RXR Dual Agonists
5.2.4. Others (Novel/Next-Generation Retinoic Acid Derivatives)
Chapter 6. Retinoic Acid Pathway Therapeutics Market Segmentation 2: By Product Type, Estimates & Trend Analysis
6.1. Market Share by Application, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Application:
6.2.1. Cancer Treatment
6.2.1.1. Acute Promyelocytic Leukemia
6.2.1.2. Skin Cancer
6.2.1.3. Other Cancer Treatment
6.2.2. Dermatological Disorders
6.2.2.1. Acne
6.2.2.2. Psoriasis
6.2.2.3. Eczema
6.2.2.4. Others
6.2.3. Autoimmune Disorders
6.2.4. Others (e.g., Neurological Disorders, Respiratory Diseases)
Chapter 7. Retinoic Acid Pathway Therapeutics Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administration:
7.2.1. Oral
7.2.2. Topical
7.2.3. Intravenous
7.2.4. Others
Chapter 8. Retinoic Acid Pathway Therapeutics Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channel:
8.2.1. Rx
8.2.2. OTC
Chapter 9. Retinoic Acid Pathway Therapeutics Market Segmentation 4: By End-users, Estimates & Trend Analysis
9.1. Market Share by End-users, 2023 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End-users:
9.2.1. Hospitals and Clinics
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
9.2.4. Research Institutes
Chapter 10. Retinoic Acid Pathway Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Retinoic Acid Pathway Therapeutics Market, Regional Snapshot 2023 & 2031
10.2. North America
10.2.1. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2031
10.2.3. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
10.2.4. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
10.2.5. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
10.2.6. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2019-2031
10.3. Europe
10.3.1. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2031
10.3.3. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
10.3.4. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
10.3.5. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
10.3.6. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2019-2031
10.4. Asia Pacific
10.4.1. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2031
10.4.3. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
10.4.4. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2019-2031
10.4.5. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
10.4.6. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2019-2031
10.5. Latin America
10.5.1. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2031
10.5.3. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
10.5.4. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
10.5.5. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
10.5.6. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2019-2031
10.6. Middle East & Africa
10.6.1. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2031
10.6.3. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
10.6.4. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
10.6.5. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
10.6.6. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2019-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Roche Holding AG
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Route of Administration
11.2.1.3. Financial PerProduct Typeance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Bristol-Myers Squibb
11.2.3. Allergan (AbbVie)
11.2.4. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
11.2.5. Teva Pharmaceutical Industries Ltd.
11.2.6. Sun Pharmaceutical Industries Ltd.
11.2.7. Valeant Pharmaceuticals (Bausch Health Companies Inc.)
11.2.8. Mylan N.V.
11.2.9. TetraLogic Pharmaceuticals
11.2.10. Ortho Dermatologics
11.2.11. Kayothera
11.2.12. Ionis Pharmaceuticals
11.2.13. TetraLogic Pharmaceuticals
11.2.14. Dermira (Eli Lilly and Company)
11.2.15. Hovione
11.2.16. Phosphagenics Limited
11.2.17. Ligand Pharmaceuticals
11.2.18. Aclaris Therapeutics
11.2.19. Orphazyme A/S
11.2.20. Cipla Ltd.
11.2.21. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們